Breaking
UKNew York Times executive fatally shot in California, parents-in-law arrestedDEAirstrike on market and bridge in Kyauktaw leaves at least 49 deadDEMan critically injured in gas cylinder explosion in HamburgPLDramatic rescue operation on the Mona Strait after a boat with migrants capsizedRUThree people died in an accident with six cars in KrasnoyarskINTLOpenAI abandons GPT-6.1 Astra release after safety failures and admits unauthorized access to Australian government systemsCNSafety tips for railway travel during the National Day holiday: Public security organs call for civilized riding to prevent fraudAUMan pleads guilty to culpable driving causing death after hitting pedestrian outside Melbourne pop culture conventionRUThe largest number of victims of Ukrainian Armed Forces attacks was recorded in the Belgorod, Kherson, Zaporozhye and Kursk regions, as well as in the LPRDEBiontech is shrinking after the Corona boom, the federal government is selling shares and fighting against Chinese influenceUKNew York Times executive fatally shot in California, parents-in-law arrestedDEAirstrike on market and bridge in Kyauktaw leaves at least 49 deadDEMan critically injured in gas cylinder explosion in HamburgPLDramatic rescue operation on the Mona Strait after a boat with migrants capsizedRUThree people died in an accident with six cars in KrasnoyarskINTLOpenAI abandons GPT-6.1 Astra release after safety failures and admits unauthorized access to Australian government systemsCNSafety tips for railway travel during the National Day holiday: Public security organs call for civilized riding to prevent fraudAUMan pleads guilty to culpable driving causing death after hitting pedestrian outside Melbourne pop culture conventionRUThe largest number of victims of Ukrainian Armed Forces attacks was recorded in the Belgorod, Kherson, Zaporozhye and Kursk regions, as well as in the LPRDEBiontech is shrinking after the Corona boom, the federal government is selling shares and fighting against Chinese influence
Newsgather
All StoriesWorldSportsFinanceTechScienceHealthCultureClimatePoliticsSpace
BackYanchen Yuhua Biomedical cooperates with QuantHealth to use AI platform to support clinical development of oncology drugs
Yanchen Yuhua Biomedical cooperates with QuantHealth to use AI platform to support clinical development of oncology drugs
Developing
自由时报1 hour agoBusiness2 min readChinaView original

Yanchen Yuhua Biomedical cooperates with QuantHealth to use AI platform to support clinical development of oncology drugs

YanchenYuhua MedicalQuantHealth

Quick Look

  • Yuhua Biomedical, a subsidiary of Yanchen Biotechnology, announced its cooperation with QuantHealth of the United States, using its AI clinical trial simulation platform to support the combination of oncology expertise and artificial intelligence, and planning and evaluating clinical development strategies based on evidence.
  • Chairman Huang Zhongyang said that this cooperation represents an important milestone for the company in the integration of new drug research and development and smart medical care.

AI-generated summary

Why It Matters

Yanchen Biotech is a listed company on the Taiwan Stock Exchange, and its subsidiary Yuhua Biotech focuses on the development of new tumor therapies. This cooperation aims to introduce the AI ​​clinical trial simulation platform of QuantHealth in the United States to improve clinical development efficiency and scientific decision-making.

Font size

Yanchen and Huang Zhongyang, chairman of Yuhua Biomedical. (File photo)

[Reporter Chen Yongji/Taipei Report] Yuhua Biomedical, a subsidiary of Xingai Yanchen Biotechnology (4732), announced that it has cooperated with QuantHealth, a US company, to support the planning and evaluation of clinical development strategies through its AI clinical trial simulation platform, and to cooperate to combine oncology expertise with artificial intelligence to support evidence-based development decisions.

Yuhua Biomedical, committed to developing novel oncology therapies, today announced a collaboration with QuantHealth, a market leader in AI-driven clinical trial simulations. Yanchen said that through this cooperation, Yuhua Biomedical will be able to use QuantHealth's computing power to support clinical development planning, help evaluate development options and use research resources more wisely.

Please read on...

Yanchen pointed out that this cooperation represents the integration of the huge functions of AI into drug research and development methods by Yuhua Biomedicine. It symbolizes an important milestone in the combination of new drug research and development and smart medical technology by Yuhua Biomedicine. It demonstrates the company's determination to use innovative technology to promote clinical development and continue to create long-term value for patients and investors.

Huang Zhongyang, Chairman of Yuhua Biomedical, said, "Our partnership with QuantHealth demonstrates our determination to introduce advanced analytical tools. We see artificial intelligence as a way to challenge assumptions, explore alternatives, and strengthen the evidence supporting our development strategies. This approach combines in-house developed treatment technologies with access to external expertise and expertise. That is, AI-driven clinical trial insights can be combined with the company's existing research and clinical activities. AI-generated insights are considered in the context of existing scientific evidence and expert judgment."

Grasp the economic pulse with one hand. Click here to subscribe to Free Finance Youtube channel

What to Watch

AI outlook — possibilities, not facts

  • Yuhua Biomedical will begin using the QuantHealth platform for drug clinical development simulations in the next few months.

    Likely · Within months

Open Questions

  • What is the specific amount of cooperation and the length of the contract?
  • Which specific oncology drug development projects will the QuantHealth platform be applied to at Yuhua Biomedical?
  • When is this collaboration expected to begin producing tangible results?

Related Topics

Yanchen
PeopleHuang Zhongyang
OrganizationsYanchen BiotechnologyYuhua MedicalQuantHealth
PlacesTaipeiUnited States
TopicsYuhua MedicalQuantHealthAI clinical trialsOncology therapyHuang ZhongyangNew drug research and development
This article was originally published by 自由时报.

Related Stories

Guoguang's stock price surged more than 5% due to sudden influx of buying orders during the session.
Developing·

Guoguang's stock price surged more than 5% due to sudden influx of buying orders during the session.

The stock price of Jinguoguang (6209) suddenly received an influx of buying orders during the session today. It once rose by more than 5%, and rose 2.38% to 81.8 yuan at nearly 11:10. The company benefited from the growth in shipments of infrared thermal lens lenses, and its revenue hit a record high in August. The cumulative revenue in the first eight months increased by nearly 70% year-on-year. Foreign capital has continued to be oversold recently, and investors need to pay attention to subsequent fluctuations.

自由时报
1 min read
Multi-department collaboration promotes the "Spring Rain Moistening Seedlings" special action to help the development of small and medium-sized enterprises
Developing·

Multi-department collaboration promotes the "Spring Rain Moistening Seedlings" special action to help the development of small and medium-sized enterprises

This year, nine departments jointly launched a special campaign to help small and micro business entities develop the "Spring Rain and Moisten Seedlings". By the end of July, they had responded to more than 29,400 tax and fee appeals, established 127 collaboration mechanisms, and shared 974 million pieces of data. The action emphasizes rapid response, accurate demand capture and stable policy supply, promotes direct access to enterprise-friendly policies and promotes small and medium-sized enterprises to thrive in a fair, transparent and warm ecosystem.

中国新闻网
3 min read
Lianjia Investment Holding's stock price rises to the limit, lights up on the eve of the Law Conference
Developing·

Lianjia Investment Holding's stock price rises to the limit, lights up on the eve of the Law Conference

After Lianjia Investment Holdings (3717) transformed into a holding company, it has been deeply involved in the fields of automotive optoelectronics, AI smart cities, Micro-LED CPO optical communications, military drones and robots. Today, the stock price appeared in advance and the market price limit reached 27.85 yuan. As of 10:25, the trading volume reached 16,400 contracts, and the number of orders to buy at the upper limit price exceeded 6,300. The company's consolidated revenue in August was 505 million yuan, an annual increase of 10.01%. The cumulative revenue in the first eight months was 4.551 billion yuan, an annual increase of 891.25%. The net profit after tax in the first half of the year was 240 million yuan, an annual increase of 403.79%. The after-tax earnings per share were 1.15 yuan, turning a loss into a profit. The shipment of high-margin automotive light sources is driven by the increase in the production of fuel vehicles and HEVs by international automakers. The exchange benefits from the appreciation of the US dollar and the expected mass production of dozens of products by the new plant in Mexico in Q4 are supportive.

自由时报
2 min read
The first area of Wuhan Innovation Zone is launched, marking that the "Koi Plan" has entered the substantial implementation stage
Developing·

The first area of Wuhan Innovation Zone is launched, marking that the "Koi Plan" has entered the substantial implementation stage

The launch of Guangbutun Koi Park, the first development area of ​​Wuhan Innovation Zone, marks the transition of the "Koi Plan" from top-level design to substantial implementation. The park has a total construction area of ​​approximately 93,000 square meters, with a usable area of ​​42,000 square meters in the first phase, and more than 100 projects in reserve. Through the symbiotic development of urban renewal and scientific and technological innovation, we explore a new Silicon Alley economic model that integrates the three areas of "campus, park, and community" and provide full-chain services for the transformation of scientific and technological achievements.

中国新闻网
2 min read
Shanghai Economic Development Report: The integration of culture, business, tourism and sports exhibitions promotes the construction of an international consumption center city
Developing·

Shanghai Economic Development Report: The integration of culture, business, tourism and sports exhibitions promotes the construction of an international consumption center city

The Institute of Economics of the Shanghai Academy of Social Sciences released the "Shanghai Economic Development Report (2026): Construction of an International Consumption Center City", pointing out that the integrated development of culture, business, tourism and sports exhibitions is an important way for Shanghai to promote consumption upgrades and cultivate new increments. It is also a key to improving the energy level and core competitiveness of an international consumption center city. The report analyzes that the Shanghai consumer market shows significant characteristics of scale expansion, energy level improvement, circle diffusion, and stratification. However, it faces shortcomings such as insufficient adaptability on the supply side. It recommends upgrading consumer infrastructure, enriching scene supply, optimizing policy tools, promoting the deep integration of cultural, commercial, tourism and sports exhibition institutions, strengthening original IP, strengthening technological empowerment, improving the industrial ecology and international layout, activating inbound consumption potential, accurately matching the needs of key groups, and promoting the coordinated development of the consumer market in the Yangtze River Delta and the wider region.

中国新闻网
3 min read
More on this topicYanchen